University of Paris

About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Transplantation. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.

Critical exponents from field theory

Abstract: We present a detailed study of the methods of summation based on Borel transformation and conformai mapping, which we have used to calculate critical exponents of the n -vector model through field theoretical methods. In particular we discuss the sensitivity of the results to various changes in the summation procedure.

Spectral asymptotics in the semi-classical limit

Abstract: Semiclassical approximation addresses the important relationship between quantum and classical mechanics. There has been a very strong development in the mathematical theory, mainly thanks to methods of microlocal analysis. This book develops the basic methods, including the WKB-method, stationary phase and h-pseudodifferential operators. The applications include results on the tunnel effect, the asymptotics of eigenvalues in relation to classical trajectories and normal forms, plus slow perturbations of periodic Schrodinger operators appearing in solid state physics. No previous specialized knowledge in quantum mechanics or microlocal analysis is assumed, and only general facts about spectral theory in Hilbert space, distributions, Fourier transforms and some differential geometry belong to the prerequisites. This book is addressed to researchers and graduate students in mathematical analysis, as well as physicists who are interested in rigorous results. A fairly large fraction can be (and has been) covered in a one semester course.

Escherichia coli Physiology in Luria-Bertani Broth

Abstract: Luria-Bertani broth supports Escherichia coli growth to an optical density at 600 nm (OD600) of 7. Surprisingly, however, steady-state growth ceases at an OD600 of 0.3, when the growth rate slows down and cell mass decreases. Growth stops for lack of a utilizable carbon source. The carbon sources for E. coli in Luria-Bertani broth are catabolizable amino acids, not sugars.

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Abstract: BACKGROUND: Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia, which may contribute to cardiovascular disease and adverse clinical outcomes. Calcimimetics target the calcium-sensing receptor and lower parathyroid hormone levels without increasing calcium and phosphorus levels. We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride. METHODS: Patients who were receiving hemodialysis and who had inadequately controlled secondary hyperparathyroidism despite standard treatment were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients) for 26 weeks. Once-daily doses were increased from 30 mg to 180 mg to achieve intact parathyroid hormone levels of 250 pg per milliliter or less. The primary end point was the percentage of patients with values in this range during a 14-week efficacy-assessment phase. RESULTS: Forty-three percent of the cinacalcet group reached the primary end point, as compared with 5 percent of the placebo group (P<0.001). Overall, mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group (P<0.001). The serum calcium-phosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group (P<0.001). Cinacalcet effectively reduced parathyroid hormone levels independently of disease severity or changes in vitamin D sterol dose. CONCLUSIONS: Cinacalcet lowers parathyroid hormone levels and improves calcium-phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.